Haijun Sun

Haijun Sun is the current Chief Scientific Officer of ONA Therapeutics. Prior to this role, they were the Head of Antibody Pharmacology at GSK from 2017 to 2021. From 2015 to 2017, they were the Vice President of Antibody Development at Tizona Therapeutics, Inc., where they were responsible for antibody discovery strategies, managing CROs/CMOs, and building core in-house antibody discovery, protein expression, and bioanalytical capabilities. From 2012 to 2015, they were the Vice President of Biological Products at F-Star Biotechnology Ltd. Prior to this, they were the Director of Preclinical Research Project Management & Portfolio Mangement and Business Development at ImClone Systems from 2009 to 2012, where they were responsible for project planning, portfolio management, budget planning, business development, and administration. Haijun was also the Associate Director of Protein Sciences at ImClone Systems from 2009 to 2012, where they managed an 18-member group, participated in budget planning, technology development, goal-setting, and other managerial activities.

Haijun Sun began their education in 1991, when they earned a PhD in Biochemistry from the University of Cincinnati. Haijun then pursued an MBA in Management and Finance from NYU Stern School of Business, which they completed in 2004. In 2011, they attended a Project Management Workshop at the University of California, Berkeley. Haijun also took a BD Basic course and a BD course in Boston, though it is unclear when these courses were taken.